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KAJIAN KETELAPAN DAN BIOKEPEROLEHAN BUPARVAQUONE, 
SUATU SEBATIAN PELOPOR ANTILEISMANIAL DALAM MODEL 
HAIWAN 
 
ABSTRAK 
Leishmaniasis merupakan suatu kumpulan penyakit parasit yang disebabkan oleh  
genus Leishmania yang kini adalah endemik di lapan puluh lapan negara. Penyakit 
ini wujud dalam dua bentuk utama, iaitu leishmaniasis kulitan dan visera. Sebatian 
antimoni pentavalensi merupakan kaedah yang paling umum digunakan untuk 
mengubati semua penyakit jenis ini. Kajian in vitro dan in vivo menunjukkan 
buparvaquone (BPQ) sebagai suatu sebatian yang berpotensi untuk digunakan 
terhadap jangkitan Leishmania donovi. Dalam membangunkan formulasi oral BPQ, 
penentuan ciri-ciri biofarmaseutikal seperti keterlarutan dan ketelapan drug perlu 
dikaji terlebih dahulu. Kajian kestabilan di peringkat awal menunjukkan bahawa 
sampel BPQ yang dilarutkan dalam metanol  dan asetonitril membentuk sebatian 
degradasi yang belum dikenalpasti apabila didedahkan kepada cahaya. Kadar 
degradasi juga didapati meningkat apabila didedahkan kepada cahaya ultra 
lembayung. Kajian keterlarutan BPQ dalam pelbagai jenis larutan penimbal piawai 
(pH 1.2 hingga 7.5) telah dikaji dan didapati keterlarutan tertinggi tidak melebihi 210 
ng/ml. BPQ didapati stabil dalam bendalir gastrik dan usus simulasi, di mana 
degradasi adalah kurang dari 5%. Keputusan ini mencadangkan bahawa BPQ akan 
tetap stabil dalam saluran perut usus sebelum penyerapan berlaku. Ketelapan atenolol 
and propranolol telah dikaji dalam model tikus in situ pada kepekatan DMSO yang 
berbeza (1-5%). Tiada perubahan signifikan (p>0.05) ke atas nilai purata petunjuk-
petunjuk ketelapan tersebut. Nilai yang didapati ini adalah sejajar dengan nilai 
ketelapan yang dilaporkan sebelum ini. Keputusan kajian ini menunjukkan integriti 
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membran tisu usus tikus tidak dipengaruhi oleh kehadiran DMSO sehingga sebanyak 
5%. Drug yang berketerlarutan rendah dalam air sering memberi masalah dalam 
kajian ketelapan kerana keterlarutan yang rendah dan penyerapan tidak spesifik 
menjadi punca kepada anggaran ketelapan yang tidak tepat. Oleh kerana BPQ adalah 
suatu sebatian yang berketerlarutan rendah dalam air, maka kajian ketelapan 
dilakukan dengan kehadiran 5% DMSO sebagai pelarut bersama. Nilai ketelapan 
purata bagi BPQ adalah 0.912 x 10-4 cm/s dan ini menunjukkan bahawa ia adalah 
sebatian jenis kelas II, di mana ia adalah berketelapan tinggi walaupun 
berketerlarutan rendah berpandukan kepada Sistem Klasifikasi Biofarmaseutikal 
(SKB). Sistem Penyampaian Drug Swa-Mikroemulsifikasi (SPDSM) merupakan 
suatu formulasi oral yang boleh digunakan untuk drug kelas II SKB untuk 
meningkatkan keterlarutan dan biokeperolehan. Perkembangan dan penyaringan 
formulasi oral SPDSM telah dilakukan berdasarkan kepada keputusan kajian 
keterlarutan pelbagai eksipien, gambarajah fasa untuk penentuan kawasan swa- 
mikroemulsifikasi, analisis saiz butiran dan masa emulsifikasi. Pelarutan in vitro dan 
kajian farmakokinetik telah dilakukan ke atas formulasi yang optimum yang terdiri 
daripada Capryol 90 (9.82 %w/w) dan campuran Cremophor EL/Labrasol (4:1) 
(88.40 %w/w) dan BPQ 1.78 %w/w. Formulasi ini menghasilkan saiz butiran tyang 
terkecil berukuran 18 nm. Kaedah analisis fasa terbalik HPLC-UV yang berbeza 
telah diperkembangkan dan disahsahihkan untuk penentuan BPQ dalam pelbagai 
matriks biologi. Kajian biokeperolehan BPQ telah dilakukan dalam arnab jantan 
putih New Zealand. Parameter farmakokinetik telah ditentukan untuk kedua-dua 
intravena dan formulasi oral bagi BPQ dan nilai-nilai min Cmax, Tmax dan AUC(0-36) 
adalah 999.83 ng/ml, 0.25 jam, 2872.71 ng.jam/ml dan 171.74 ng/ml, 7.33 jam, 
3456.38 ng.jam/ml masing-masing. Biokeperolehan mutlak adalah 40.10 %.  
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EVALUATION OF PERMEABILITY AND BIOAVAILABILITY OF A LEAD 
ANTILEISHMANIAL COMPOUND BUPARVAQUONE IN ANIMAL 
MODELS 
 
ABSTRACT 
Leishmaniasis is a group of parasitic disease caused by the protozoan parasites of the 
genus Leishmania and is currently endemic in 88 countries. This disease occurs in 
two major forms, cutaneous and visceral leishmaniasis. Pentavalent antimonials are 
the most widely used therapy for all forms of the disease. In in vitro and in vivo 
studies buparvaquone (BPQ) has been found to be a promising lead compound for 
the treatment of Leishmania donovani infections. The successful development of oral 
drug delivery formulation for BPQ requires determination of the biopharmaceutical 
properties mainly solubility and permeability. In preliminary stability studies, the test 
samples of BPQ in methanol and acetonitrile form unknown degradation compounds 
when exposed to the light and the rate of degradation was increased in the presence 
of UV light. BPQ solubility studies were carried out in various standard buffer 
solutions (pH 1.2 to 7.5) and the solubility was found to be not more than 210 ng/ml. 
BPQ was stable in both simulated gastric and intestinal fluids with < 5% degradation. 
These results suggest that BPQ would be stable in the gastrointestinal tract prior to 
absorption. Permeability of atenolol and propranolol were carried out in rat in situ 
model at various concentrations of dimethyl sulfoxide (DMSO, 1-5%). There was no 
significant alteration (p>0.05) in the mean values of the permeability markers. The 
values agreed with previously reported permeability values. The results indicate that 
the membrane integrity of the rat intestinal tissues was not affected by the presence 
of up to 5% DMSO. Poorly water soluble drugs often cause difficulties in 
permeability studies due to their poor solubility limitation and non-specific 
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adsorption which lead to inaccurate estimation of permeability. Since BPQ is a 
poorly water soluble compound the permeability study was carried out in the 
presence of 5% DMSO as a co-solvent. The mean permeability value for BPQ was 
0.912 x10-4 cm/s indicating that it is a class II compound which is a highly permeable 
and poorly water soluble compound according to the biopharmaceutical classification 
system (BCS). Self-Microemulsifying drug delivery system (SMEDDS) is a feasible 
oral formulation approach for BCS class II drugs since it increases their solubility 
and bioavailability. Oral SMEDDS formulation development and screening was done 
based on results obtained from solubility in various excipients, phase diagrams for 
identifying microemulsification region, droplet size analysis and emulsification time. 
In vitro dissolution and pharmacokinetic studies were performed with the optimized 
formulation which is composed of Capryol 90 (9.82% w/w) and mixture of 
Cremophor EL/Labrasol (4:1) (88.40% w/w) and BPQ (1.78% w/w). This 
formulation yielded the smallest droplet size of 18 nm. Different RP-HPLC-UV 
analytical methods were developed and validated for determining BPQ in the various 
biological matrices. Bioavailability study of BPQ was conducted in healthy white 
New Zealand male rabbits. Pharmacokinetic parameters were calculated for both i.v 
and the optimized oral formulation of BPQ and the mean Cmax, Tmax and AUC (0–36) 
were 999.83 ng/ml, 0.25 hour, 2872.71 ng.hour/ml and 171.74 ng/ml, 7.33 hour, 
3456.38 ng.hour/ml respectively. Absolute bioavailability was found to be 40.10%.  
 
CHAPTER 1 
INTRODUCTION  
 
Tropical diseases are infectious diseases that occur uniquely in tropical and 
subtropical regions. In the Special Programme for Research and Training in Tropical 
Diseases of the World Health Organization (WHO/TDR), various 
international/national bodies and philanothropic foundations focus on neglected 
infectious diseases that mainly affect poor and marginalized populations in the 
developing regions of America, Asia, and Africa. Neglected Tropical Diseases 
(NTDS) cause approximately 534,000 deaths annually. These include bacterial, 
protozoan and helminth tropical infectious diseases such as leishmaniasis, African 
trypanosomiasis, dengue fever, malaria, schistosomiasis, tuberculosis, chagas 
disease, leprosy, lymphatic filariasis and onchocerciasis. Although leprosy, 
tuberculosis, cholera and yellow fever do not occur in the tropics their highest 
incidence in the tropics justify their inclusion in tropical diseases (Nwaka and 
Hudson, 2006; Hotez et al., 2007).  
 
Some tropical diseases are very rare but they may occur in sudden epidemics, such as 
the ebola hemorrhagic fever, marburg haemorrhagic fever and lassa fever. There are 
hundreds of different tropical diseases which are less known such as oropouche 
fever, lobomycosis, west nile disease, labrea fever, rocio disease, mapucho 
hemorrhagic fever, trachoma, guinea worm disease and chikungunya (Tropical 
disease, 2008).  
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1.1 Leishmaniasis 
1.1.1 Epidemiology 
Leishmaniasis is a major widespread parasitic disease and is caused by the protozoan 
haemoflagellates of the genus Leishmania. There are at least 20 species of leishmania 
which are transmitted by 30 species of sandflies and each may cause disease specific 
to the species and the host response. It is endemic in many parts of the world and the 
geographical distribution of the disease is shown in Figure 1.1. There are several 
forms of the disease named by their clinical presentation including cutaneous 
leishmaniasis (CL), visceral leishmaniasis (VL) and mucocutaneous leishmaniasis 
(MCL). Each of these forms of disease is caused by different species of sandflies 
found in different regions of the world. Table 1.1 shows the common species that 
cause leishmaniasis in different geographical locations. Old World CL in humans is 
associated with members of L. aethiopica, L. major, and L. tropica complex while L. 
mexicana and L. braziliensis complex transmit New World CL. VL is caused by L. 
donovani and L. infantum in the Old World regions while L. chagasi is primarily 
responsible for visceral disease in the New World (Herwaldt, 1999; Bailey and 
Lockwood, 2007; Davies et al., 2003). 
 
The disease is prevalent worldwide and threatens 350 million men, women and 
children, affecting 88 countries of which 72 are developing countries and 13 of them 
are among the least developed. High occurrence of VL is found in 65 countries and 
90% of VL cases occur in poor rural and suburban areas of 5 countries namely 
Bangladesh, India, Nepal, Sudan and Brazil. Majority of CL cases occur in 7 
countries namely Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia and Syria  
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 Figure 1.1 Global distribution of leishmaniasis (Davies et al., 2003). 
 
Table 1.1 Leishmaniasis disease patterns and common organisms in different 
geographical locations. 
 
Clinical disease Leishmaniasis species Geographical location
Cutaneous leishmaniasis L. tropica complex: L. tropica, L. aethiopica and L. major. Old World 
 
L. mexicana complex:  L. Mexicana, 
L.pifanoi , L. amazonensis, L. garnhami 
and L. venezuelensis . 
New World 
 
L. braziliensis complex: L. peruviana , 
L.guyanensis L. panamensis L. lainsoni 
and L. colombiensis. 
New World 
 L. infantum Old World 
 L. chagasi New World 
Visceral leishmaniasis L. donovani complex: L. donovani,  L. infantum Old World 
 L. chagasi New World 
 L. tropica Old World 
 L. amazonensis New World 
Mucocutaneous 
leishmaniasis 
L. braziliensis complex: L. braziliensis , 
L.guyanensis and L. panamensis New World 
 L. Mexicana New World 
 L. tropica and  L. major Old World 
 
Old World: N.Africa, South Asia, Middle East, Tunisia Ethiopia, Kenya, India, 
Sudan, Bangladesh, China, Central and West Asia, Central and South 
America, Mexico, Belize, Guatemala and Ecuador. 
 
New World: Venezuela, Brazil, Peru, French Guiana, Guyana, Surinam, Panama and 
Costa Rica 
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and 90% of MCL occur in Bolivia, Brazil and Peru (Bailey and Lockwood, 2007; 
Piscopa and Mallia, 2006). 
 
1.1.2 Vector transmission  
The leishmania species belongs to the class Kinetoplastida and family 
Trypanosomatida. The sandflies (2-3 mm long) which are the vectors that transmit 
the disease are from genus Phlebotomus in the Old World and Lutzomyia and 
Psychodopygus in the New World. Sandflies are relatively weak, noiseless fliers; 
they rest in dark and moist places and are typically more active in the evening and 
night. These vectors are nocturnal by nature and it is the females that prey on blood. 
The parasites are introduced into the host (human) through the bite of an infected 
female sandfly  (Herwaldt, 1999).   
 
 
1.1.3 Life cycle 
During the life cycle, the parasite exists in two forms; amastigote form in human and 
promastigote form in sand fly.  The various stages of the leishmania life cycle is 
shown in Figure 1.2. The female sandflies inject the infective stage metacyclic 
promastigotes (elongated motile and with an anterior flagellum) during blood meals 
(1). Metacyclic promastigotes that reach the puncture wound are phagocytized by 
macrophages (2) and undergoes transformation into amastigotes (3). Amastigotes (2-
3 µm in diameter) multiply by binary fission in the macrophages and proceed to 
infect other mononuclear phagocytic cells (4). These amastigotes will affect different 
tissues of the body, depending on which leishmaniasis species is involved. These 
differing tissue specificities cause the different clinical manifestations of the various  
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 Figure 1.2  Leishmania life cycle (Source: http://en.wikipedia.org.). 
 
 
forms of leishmaniasis. Sandflies become infected during blood meals from an       
infected host when they ingest macrophages infected with amastigotes (5, 6). In the 
sandfly midgut, the parasites differentiate into promastigotes (7), which multiply, 
differentiate into metacyclic promastigotes and migrate to the pharynx and proboscis 
(8) (Leishmaniasis, 2007; Chappuis et al., 2007). 
 
1.1.4 Clinical manifestations 
1.1.4 (a) Visceral leishmaniasis or Kala-azar 
VL comprises a broad range of manifestations of infection. The clinical symptoms 
are characterized by fever, weakness, night sweats and weight loss and these 
symptoms continue over weeks to months. Lymphadenopathy, hyperpigmentation 
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and hepatosplenomegaly (spleen much larger than the liver) are of common 
occurrence in VL. Anaemia, leucopenia, or thrombocytopenia, and 
hypergammaglobulinaemia are also frequently manifested symptoms. Untreated or 
progressing disease can produce profound cachexia, multisystem disease, bleeding 
from thrombocytopenia, susceptibility to secondary infections and death may rapidly 
follow (Chappuis et al., 2007; Singh et al., 2006). 
 
 
1.1.4 (b) Cutaneous and mucocutaneous leishmaniasis 
Cutaneous forms of the disease normally produce skin ulcers on the exposed parts of 
the body such as face, arms and legs. It starts as a papule at the site of a bite, 
increasing in size, causing ulcer. It may take 3-18 months to heal in typical cases. 
The incubation period lasts from 2 weeks to months and cases up to 3 years have 
been reported in Old World CL. In New World CL, the incubation period is usually 
2-8 weeks (Piscopa and Mallia, 2006). In the Old World CL most of the lesions 
appear in the form of nodules, papules or nodule ulcers, but most New World CL 
may begin with ulcerative lesions. In MCL the lesions affect the mucocutaneous 
membranes of the nose, mouth, and throat cavities causing partial or total destruction 
of the surrounding tissues (Bailey and Lockwood, 2007; Desjux, 2004). The 
incubation period for MCL is 1-3 months, but it may occur many years after the 
initial cutaneous ulcer has healed. Mucosal type occurs in South American cases of 
CL (espundia). This causes difficulty in eating and an increased risk for secondary 
infection, which carries considerable mortality (Piscopa and Mallia, 2006). 
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1.1.5 Diagnosis  
1.1.5 (a) Visceral leishmaniasis 
Diagnosis of VL is routinely based on microscopic detection of amastigotes in 
smears of tissue aspirates or biopsy samples. An aspirate or biopsy of the bone 
marrow is frequently the tissue of choice, with sensitivities in the 55-97% range. The 
gold standard for diagnosing VL is parasite identification in tissue smears with 
splenic aspirate being more sensitive than bone marrow or lymph node aspirates. 
Lymph node aspirate smears (sensitivity 60%) or biopsy, and splenic aspirates 
(sensitivity 97%) may also be taken for diagnosis. The parasite may also be cultured 
from microscopy negative tissue samples on special media such as Novy, McNeal or 
Nicolle medium or inoculated into animals such as hamsters (Singh et al., 2006). 
Direct Agglutination Test (DAT) is commonly used diagnosis for VL and it is easy 
to use in the field. DAT has been shown to be sensitive and quite specific (sensitivity 
of 91-100% and a specificity of 72-100%). However its use is limited due to the non 
availability of standardized antigen and adaptability especially in the rural centres. 
Immunochromatographic rapid strip testing of blood from a finger prick for 
leishmanial rK39 antibody has been used successfully in the field of serodiagnosis 
with a sensitivity of 90-100% in patients showing symptoms. Leishmania DNA can 
be detected in the tissue aspirates and peripheral blood using polymerase chain 
reaction (PCR), with sensitivities in the range of 70-93% in peripheral blood. PCR 
and in situ hybridisation have been used to amplify DNA sequences of the parasite in 
biopsy material and is highly sensitive for the diagnosis of VL and can be used to 
monitor therapeutic response (Piscopo and Mallia, 2006; Chappuis et al., 2007; 
Singh et al., 2006). A new commercial latex agglutination test (KATEX) was used 
for preliminary testing to detect the leishmanial antigen in patient’s urine with 
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sensitivity in the range of 68-100% and 100% specificity. However, this test is still 
under the preliminary phase evaluation and its commercialization is still far from 
reality (Singh et al., 2006; Davies et al., 2003).  
 
1.1.5 (b) Cutaneous leishmaniasis 
Tissue aspirate, scraping and fresh skin biopsies are employed frequently to obtain 
samples. Microscopical examinations of skin scrapings or biopsy specimens taken 
from the edge of lesions are used for the diagnosis of CL. This method is rapid and 
economical but has limited sensitivity, especially for chronic lesions. Monoclonal 
antibodies are used for identification, but a direct analysis of clinical specimens is 
better achieved using PCR. Antibody detection is less sensitive due to the lack of 
significant antibody production in CL. Other means of diagnosing CL include the 
Montenegro (leishmanin) skin test, which detects specific cutaneous delayed-type 
hypersensitivity. It involves intradermal injection of L.mexicana antigen, and 
monitoring for a local reaction. Limitations of this test include its inability to 
distinguish between current and past infection, as well as report of false positivity in 
other skin infections (Piscopo and Mallia, 2006; Bailey and Lockwood, 2007).  
 
1.1.6 Current chemotherapy for cutaneous and visceral leishmaniasis 
Currently available drugs which are used for treatment of leishmaniasis include 
meglumine antimonite (Glucantime, Aventis), sodium stibogluconate (Pentostam, 
Glaxo SmithKline), amphotericin B(Bristol-Myers Squibb), amphotericin B lipid 
formulation (AmBiosome®, Gilead) and pentamidine (Aventis).  
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1.1.6 (a) Pentavalent antimonials 
For the past 50 years, treatment for both CL and VL was mainly dependent on 
pentavalent anitimonials, sodium stibogluconate (Pentostam) and meglumine 
antimoniate (Figure 1.3). The antimonials were introduced in 1945 and they are 
effective for the treatment of some forms of leishmaniasis. In recent years it has been 
found that there is an increase in the parasite resistance for these drugs. These 
antimonials are less effective against VL and MCL in the Bihar state of India 
because of poor pharmacokinetics and variation in the species sensitivity, all these 
factors limiting the drugs usefulness. The standard therapy for both VL and CL 
involves daily intravenous injections for 20 days of sodium stibogluconate or 
meglumine antimoniate at a dose of 5 mg on first day and increased to maximum 
total dose of 850 mg/day (Fernando et al., 2001; Croft and Coombs, 2003; Ouellette 
et al., 2004). 
 
1.1.6 (b) Pentamidine 
Pentamidine isethionate (Figure 1.3) is an antiprotozoal agent introduced in 1952 and 
is used as a second-line antileishmanial drug for both CL and VL when antimonials 
are resistant to the parasite. The effective treatment for CL was found to be at the 
dose of 2 mg/kg administered intravenously on alternate days for 14 days. The 
treatment for VL which produces a cure rate of 70% requires a dose of 4 mg/kg on 
alternate days for a total of 40 days. However pentamidine has limitations in its use 
as an antileishmanial drug due to considerable toxicity such as hypotension, 
hypoglycemia, and nephrotoxicity. (Fernando et al., 2001; Ouellette et al., 2004). 
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1.1.6 (c) Amphotericin B 
Amphotericin B (Figure 1.3) is an antifungal agent recommended as a second-line 
drug for the treatment of VL, CL and MCL. Amphotericin B was administered at a 
dose of 0.75-1.0 mg/kg on alternate days for 30 days. Amphotericin B usage is 
limited by its  narrow therapeutic index and the side effects are fever, hypotension, 
liver failure and blood dyscrasias. (Singh et al., 2006). However the efficacy of 
Amphotericin B has been improved by the development of a liposomal formulation 
which is rapidly effective and non toxic and has been approved by FDA for treatment 
of VL in adults. It is given by IV at 3 mg/kg/day for 30 days for children with drug 
resistance VL (Croft et al., 2005; Kafetzis et al., 2005; Murray, 2004). 
 
1.1.6 (d) Other drugs and physical treatment methods 
12% methlybenzethonium chloride in soft paraffin is used for CL and the duration of 
application depends on the strain of parasite. Oral medications such as dapsone, 
allopurinol, ketaconazole, levamisole and rifampicin are also used for the treatment 
of CL. The dose of dapsone, allopurinol, ketaconazole, levamisole and rifampicin is 
1-2 mg/kg/day for six weeks, 20 mg/kg/day for 15 days, 10 mg/kg in three divided 
doses for 4 weeks, 150 mg/day on  two successive days each week for 8 weeks and 
10 mg/kg for 6 -12 weeks respectively. However these drugs have side effects such 
as hepatocellular changes, allergic reactions, vomiting, nausea and abdominal pain. 
In case of rifampicin, the body fluids become red. Allopurinol and ketaconazole or 
both in combination are also used for the treatment of VL (Fernando et al., 2001).  
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Figure 1.3 Chemical structures of (a) meglumine antimoniate, (b) sodium         
stibogluconate, (c) pentamidine and (d) amphotericin B. 
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Physical treatments like cryotherapy and thermotherapy have been used for the 
treatment of cutaneous lesions for duration of 4 weeks with a success rate from 77% 
to 100%. However their use is limited because of availability of equipment, 
secondary infections, slower healing of large scars and poor compliance (Bailey and 
Lockwood, 2007). 
 
1.1.7 Immunotherapy 
Active VL causes a defect in the immune system by causing a deficiency in 
interferon-γ production in the body. In this case, rational therapeutic approach of 
treatment would involve the stimulation of the immune system. For AIDS patients 
with VL, pentavalent antimoniate and interferon-γ with a dose of 100-400 µg/m2 
body surface/day is recommended for a course of 10-40 days. However the treatment 
is still in its early stages and requires further development. (Fernando et al., 2001). 
 
1.1.8 Drugs in development 
1.1.8 (a) Paramomycin 
Paramomycin is a non toxic aminoglycoside aminocyclitol antibiotic which is an 
effective for the treatment of both VL and CL and is currently in clinical trials. A 
suitable monotherapy regimen of paramomycin sulphate is 16 mg/kg, administered 
intramuscularly for 21 days (Singh et al., 2006). An ointment with 15% 
paramomycin and 0.5% gentamicin has been shown to be 100% effective for CL in 
BABL/c mice (Davis and Kedzierski, 2005). 
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1.1.8 (b) Miltefosine 
Miltefosine (Figure 1.4) is an alkylphosphocholine originally developed as an 
anticancer agent. Miltefosine has shown efficacy in several in vitro and in vivo 
experimental models as an effective oral drug for the treatment of VL. These 
findings led to clinical trials and registration of miltefosine for oral treatment of VL 
in India in March 2002 and for CL in Colombia in 2005. In phase 3 trials miltefosine 
cured 94 % of VL patients with a dose of 2.5 mg/kg for 28 days. Cutaneous lesions 
were healed with topical application of 6% miltefosine ointment for 2-5 weeks (Croft 
and Engel, 2006; Croft and Coombs, 2003). A study was conducted in VL male 
patients in India to evaluate the patients’ fertility and results showed that there were 
no clinically relevant changes on patients’ fertility. The major limitation of 
miltefosine is teratogenicity and is therefore not recommended for women in child-
bearing age. (Sindermann and Engel, 2006). 
 
1.1.8 (c) Sitamaquine 
Sitamaquine (Figure1.4) is a primaquine analogue (8-aminoquinolene) and was 
developed as an alternative oral drug by Walter Reed Army Institute of 
Research/Glaxo SmithKline. An initial phase I/II study showed 67% cure rate in 
patients treated with a dose of 2 mg/kg/day for a duration of 28 days in Brazil and 
92% cure rate when treated with 1.7 mg/kg daily for 28 days in Kenya for VL (Davis 
and Kedzierski , 2005; Dietze et al., 2001). Sitamaquine has mild toxicity and causes 
methemoglobinaemia (Croft et al., 2006). 
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   (a)    
 
(b) 
Figure 1.4 Chemical structures of (a) miltefosine and (b) sitamaquine. 
 
 
1.1.9 Buparvaquone 
 
Buparvaquone (BPQ), 4-hydroxy-3- [(4-tert-butylcyclohexyl) methyl] naphthalene-1, 
2-dione (Figure 1.5) is a second-generation hydroxynaphthoquinone related to 
parvaquone. It has novel features that make it a promising compound for the therapy 
and prophylaxis of all forms of theileriosis. In in vivo studies BPQ showed 
approximately twenty times more activity than parvaquone and it has been tested 
widely against Theileria annulata, T. parva and T. sergenti both in laboratory studies 
and in field trials. In an acute oral toxicological study in rat, the observed LD50 value 
for BPQ was more than 8000 mg/kg which showed BPQ has low toxicity (McHardy, 
1988). Currently BPQ has been formulated as a solution for intramuscular injection 
(Butalex, Coopers Animal Health). The Butalex injection is a safe, convenient and an 
additional alternative drug product to the existing antitheilerial products (McHardy et 
al., 1985). 
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 Figure 1.5 Chemical structure of buparvaquone (BPQ).  
 
As part of a programme to find new drugs for treatment of leishmaniasis, a series of 
hydroxynaphthoquinones were tested against Leishmania donovani in vitro and in 
vivo.  In vitro experiments showed BPQ to be 100 fold more active against L. 
donovani amastigotes than other hydroxynaphthoquinones with ED50 value of 0.005 
µM. However, in vivo experiments performed in BABL/c mice model with oral and 
subcutaneous routes with a dose of 100 mg/kg BPQ for five days resulted in 
suppression of only 35 to 62% liver amastigotes. This low activity was considered to 
be due to its poor distribution from the site of injection and poor oral bioavailability 
due to insufficient absorption (Croft et al., 1992). Butalex was injected 
intramuscularly to seven dogs which were symptomatic and parasitologically 
positive for canine visceral leishmaniasis with 4 doses of 5 mg/kg over a 12 day 
period. Only two dogs showed minor clinical improvement and as a consequence it 
was concluded that BPQ was ineffective for the treatment of symptomatic visceral 
leishmaniasis (Vexenat et al., 1998).  
 
BPQ has very poor aqueous solubility (<0.03 µg/ml), high lipophilicity (at pH 3.0 
Log D -7.02) and a pKa value of 5.70.  The low solubility and high lipophilicity are 
the most probable reasons for the low in vivo activity of BPQ against leishmaniasis 
in oral drug delivery. Furthermore BPQ metabolizes more actively with mouse and 
 15
dog hepatic microsomes in the presence of NADPH when compared to human 
hepatic microsomes. There is no reported pathway available in literature on the 
metabolism of BPQ (Mantyla et al., 2004a; Croft et al., 1992). 
 
A pharmacokinetic study has been reported for BPQ and parvaquone in cattle in 
which BPQ was administered into the neck muscles at a dose of 2.5 mg/kg. There 
was no significant variation in absorption and distribution rates for both drugs but a 
wide variation was observed in the mean plasma concentrations for BPQ (50 to 280 
ng/ml). The average elimination half life was 26.44 hours for BPQ and there was no 
intravenous data for calculating bioavailability (Kinabo and Bogan, 1988).  
 
1.1.10 Buparvaquone-oxime derivatives 
Mantyla et al. (2004a) reported that BPQ was active in in vitro studies against both 
amastigotes and promastigotes in low nanomolar range but in vivo results were 
disappointing. This finding led to the synthesis of various oxime derivatives of BPQ 
as novel antileishmania compounds. The buparvaquone oxime containing C=NOH 
group undergoes a CYP-450 dependent oxidative cleavage to BPQ (Figure 1.6). 
Buparvaquone oxime has better aqueous solubility (5.42 µg/ml) when compared to 
BPQ and other oxime derivatives such as buparvaquone-O-methlyloxime and O-
methly-buparvaquone oxime. Buparvaquone oxime derivatives have shown low in 
vitro activity against intracellular leishmania donovani amastigotes when compared 
to BPQ. The lower activity of these buparvaquone oxime compounds is most 
probably due to their slow conversion to BPQ during the experiment.  
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 Figure 1.6 Chemical structures of buparvaquone oxime derivatives. 
 
1.1.11 Water soluble prodrugs of buparvaquone-oxime and buparvaquone-O-
methlyoxime 
The phosphate prodrug approach is a widely used strategy to improve aqueous 
solubility of drugs containing hydroxyl group. Thus researchers combined the oxime 
and phosphate prodrug strategies for improving the aqueous solubility of BPQ. 
Novel water soluble phosphate prodrugs of buparvaquone-oxime and buparvaquone-
O-methlyoxime were synthesized and all the prodrugs have good aqueous solubility 
(Figures 1.7 and 1.8). The most promising prodrug is 3-(trans-4-tert-butyl-cyclo 
hexylmethyl)-2-hydroxy-[1,4]naphthoquinone-1-(O-phosphonooxymethlyoxime) or 
(Phosphonooxymethyl-buparvaquone-oxime) (Figure 1.7 b). It has good aqueous 
solubility (4.2 mg/ml) and chemical stability over the pH range of 3.0-7.4 and rapidly 
releases the parent buparvaquone oxime via chemical or enzymatic bioconversion by 
alkaline phosphatases (t1/2 4.1 min) (Figure 1.9). Parent buparvaquone-oxime has 
been suggested to be able to efficiently permeate through the intestinal wall and form 
BPQ after oxidative metabolism (Mantyla et al., 2004b).  
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           (a)                         (b)                                
Figure 1.7  Chemical structure of water soluble prodrugs of BPQ (a) 3-(trans-4-
tert-butyl-cyclohexylmethyl)-2-hydroxy-[1, 4] naphthoquinone-1-(O-
phosphono oxime) and (b) 3-(trans-4-tert-butyl-cyclohexylmethyl)-2-
hydroxy-[1,4] naphthoquinone-1-(O-phosphon ooxymethyloxime). 
 
 
 
 
 
 
 
  (a)   (b) 
Figure 1.8    Chemical structure of water soluble prodrugs of BPQ (a) 3-(trans-4-tert-
butyl-cyclohexylmethyl)-2-phosphono-[1,4]naphothaquinone-1-(O-met 
hyloxime) and (b) 3-(trans-4-tert-butyl-cyclohexylmethyl)-2-       
phosphonoox ymethoxy - [1,4]naphthoquinone-1-(O-methyloxime).  
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                  Phosphonooxymethyl-buparvaquone-oxime 
 
          Enzymatic hydrolysis 
        Alkaline phosphatases 
 
                             Buparvaquone-oxime 
                                        
       P450 oxidation 
 
         Buparvaquone 
Figure 1.9 Schematic flow chart for formation of BPQ from buparvaquone-oxime 
phosphate prodrugs.  
 
 
 
1.1.12 Buparvaquone water soluble phosphate prodrugs 
 Prodrugs release the parent drug during or after absorption by enzymatic or chemical 
hydrolysis. However a phosphate group that is directly attached to a hydroxyl group 
is not always cleaved enzymatically due to steric hindrance. Therefore researchers 
focussed on designing enzymatically labile phosphate prodrugs which release the 
drug as BPQ by hydrolysis. Aqueous solubility of the prodrugs buparvaquone-3-
phosphate and 3-phosphonooxymethyl-buparvaquone is more than 3.5 mg/ml over 
the pH range of 3.0-7.4 (Figure 1.10). These phosphate prodrugs are sufficiently 
stable in the gastrointestinal tract before their absorption and rapidly hydrolyze 
(t1/2=1.2 and 3.8 min) to the parent compound in the presence of alkaline phosphatase 
(Mantyla et al., 2004). 
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         (a)                                                        (b) 
Figure 1.10 Chemical structures of water soluble phosphate prodrugs of BPQ: (a) 
buparvaquone-3-phosphate and (b) 3-phosphonooxymethyl-
buparvaquone 
 
In in vitro activity studies phosphate prodrugs have been shown to have potent 
activity in the nanomolar range against the various species of the promastigotes and 
amastigotes due to their conversion to BPQ. Of these two phosphate prodrugs 3-
phosphonooxymethyl-buparvaquone is the more potent antileishmanial compound. 
Human skin permeation of BPQ can also be significantly improved by using 
phosphate prodrugs. 3-phosphonooxymethyl-buparvaquone was shown to be rapidly 
converted to the parent drug during skin permeation studies (Mantyla et al., 2004; 
Garnier et al., 2007). 
 
BPQ and phosphate prodrugs were evaluated by in vivo studies for both VL and CL.  
BPQ (hydrous gel and water-in-oil emulsion formulations) and phosphate prodrugs 
(anhydrous gel formulation) significantly reduce the parasite burden and lesion size 
when compared to the untreated control for CL. These findings suggest that BPQ and 
phosphate prodrugs are effective for the treatment of CL. In visceral model BPQ was 
prepared as a solution in isopropyl myristate and polyethylene glycol 400 and the 
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phosphate prodrugs were prepared in 50 mM sodium acetate buffer (pH 5.0). 
Prodrugs caused a significant decrease in the liver parasite burden when compared to 
BPQ. These results suggest that BPQ and phosphate prodrugs need to be investigated 
further for the treatment of VL (Garnier et al., 2007a). 
 
1.2 Solubility and gastrointestinal stability 
In the drug discovery process, the lead candidates must have proper physicochemical 
properties in order to have a better chance of success in the development. Solubility, 
pKa (ionization constant) and lipophilicity are the most fundamental 
physicochemical properties of a drug candidate and the determination of these 
parameters are essential in both in silico and in vitro models. Based on 
Biopharmaceutical Classification System (BCS), the drug bioavailability mainly 
depends on the aqueous solubility and the ability of molecule to permeate through 
the biological membrane (Figure 1.11). Many pharmacologically active compounds 
fail to become pharmaceutical drugs because of poor bioavailability and 
unacceptable physicochemical properties. As a consequence, solubility and 
permeability have been incorporated into drug discovery programs (Delaney, 2005; 
Huuskonen, 2001). 
 
BCS recommends determining the solubility of drug substances under physiological 
pH conditions. The experiments should be carried out at 37 ± 1 º C in aqueous media 
with a pH range of 1.2 to 7.5. To obtain accurate solubility data, the pH solubility 
profile of the compound should be determined based on its pKa. Solubility should be 
determined at pH= pKa, pH= pKa +1, pH= pKa -1, pH 1 and 7.5 (USFDA, 2000). 
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 Class I 
High Solubility 
High Permeability 
 
 Class II 
Low Solubility 
High Permeability 
 
Class III 
High Solubility 
Low Permeability 
 
 Class IV 
Low Solubility 
Low Permeability 
 
                              Figure 1.11 Biopharmaceutics Classification System. 
 
Prior to permeability studies, it is necessary to determine the stability of the drug in 
gastric and intestinal (G.I) fluids. These results will assist in obtaining accurate 
permeability values.  When conducting permeability studies in in vivo or in situ 
models there is possibility for degradation of the drug in the G.I fluids prior to 
absorption which will give rise to erroneous permeability values. Hence it is 
necessary to determine the stability of the drug in both gastric (pH 1.2) and intestinal 
(pH 6.8) conditions. 
 
USFDA, (2000) recommends conducting G.I stability by incubating the drug 
solution in these fluids at 37º C for a period that is representative of in vivo drug 
contact with these fluids. The experiments should be conducted for 1 hour in gastric 
fluids and for 3 hours in intestinal fluids.   
 
1.3 Intestinal permeability 
A major objective in the pharmaceutical industry is to develop new drugs with good 
oral bioavailability. The new chemical entities are first selected on the basis of their 
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pharmacological activity followed by sequential profiling to assess the solubility, 
absorption, distribution, metabolism, elimination and toxicity for lead selection and 
optimization (Trapani et al., 2004; Li, 2004).  
 
Drug bioavailability mainly depends on the aqueous solubility and the ability of the 
molecule to permeate through the biological membrane. Hence, the extent of in vivo 
absorption of the drug can be assessed based on solubility and in vitro permeability. 
Thus determination of intestinal permeability is one essential requirement for 
assessing the oral bioavailability of a new drug candidate at the early drug discovery 
stage (Volpe, 2008). 
 
Absorption is defined as the movement of unchanged drug from the site of 
administration into the systemic circulation. The small intestine, which consists of 
duodenum, jejunum and ileum is the most important site for drug absorption in the 
gastrointestinal tract. The small intestine permits the absorption of organic and 
inorganic chemicals/nutrients such as sugars, amino acids, lipids and vitamins and 
but prevents the entry of xenobiotics and digestive enzymes (Venkateshwarlu, 2004). 
 
Intestinal membrane is not a unicellular structure but it is a group of unicellular 
membranes parallel to one another. For drugs and nutrients to be absorbed into the 
systemic circulation they must penetrate the intestinal mucosa. The intestinal mucosa 
consists of three layers: muscularis mucosa, lamina propia and epithelial cell layer. A 
basement membrane is present below the epithelial cell layer and lamina propia lies 
between the basement membrane and muscularis mucosa, which contains connective 
tissue, blood and lymph vessels (Figure 1.12). The epithelial cell layer which 
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possesses kerkrings, villi and microvilli provides a large surface area for drug 
absorption (Venkateshwarlu, 2004; Hiremath, 2000).  
 
Figure 1.12 Anatomical details of intestinal mucosa (Source: Venkateshwarlu, 2004). 
 
Drug molecules penetrate most of the barriers in the intestine and reach the lamina 
propia. From this site, molecules either may diffuse through the blood stream or 
penetrate the central lacteal and enter the lymph. Most of the drugs reach the 
systemic circulation via the blood stream of the capillary network in the villi. The 
villi are highly and rapidly perfused by the blood stream with the blood flow rate of 
approximately 500 to 1000 times greater than lymph flow rate. Therefore the 
lymphatic system will account for only a small fraction of total amount of drug 
absorbed compared to the systemic circulation. The capillary and lymphatic vessels 
are permeable to most low molecular weight and lipid-soluble compounds. However 
capillary membrane is a more substantial barrier than the central lacteal for the 
permeation of large molecules (Venkateshwarlu, 2004; Hiremath, 2000).  
 
1.3.1 Permeability pathways 
For orally administered drugs to exert pharmacological activity, they must dissolve 
and permeate through several cellular membranes in the intestinal wall in order to 
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